Use and approval of antihypertensive agents and surrogate endpoints for the approval of drugs affecting antiarrhythmic heart failure and hypolipidemia: proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 - November 1, 1989
Saved in:
| Format: | Book |
|---|---|
| Language: | English |
| Published: |
Boston u.a.
Kluwer
1990
|
| Series: | Developments in cardiovascular medicine
112 |
| Subjects: | |
| Physical Description: | X, 230 S. |
| ISBN: | 0792307569 |
Staff View
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV004308504 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 910404s1990 |||| 10||| engod | ||
| 020 | |a 0792307569 |9 0-7923-0756-9 | ||
| 035 | |a (OCoLC)21376754 | ||
| 035 | |a (DE-599)BVBBV004308504 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 | ||
| 050 | 0 | |a RC667 | |
| 050 | 0 | |a RM345 | |
| 082 | 0 | |a 615/.71 |2 20 | |
| 245 | 1 | 0 | |a Use and approval of antihypertensive agents and surrogate endpoints for the approval of drugs affecting antiarrhythmic heart failure and hypolipidemia |b proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 - November 1, 1989 |c ed. by Joel Morganroth ... |
| 264 | 1 | |a Boston u.a. |b Kluwer |c 1990 | |
| 300 | |a X, 230 S. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Developments in cardiovascular medicine |v 112 | |
| 610 | 2 | 4 | |a United States. |b Food and Drug Administration |
| 610 | 2 | 4 | |a United States. |b Food and Drug Administration |v Congresses |
| 650 | 4 | |a Antihypertensive Agents |z United States |v Congresses | |
| 650 | 4 | |a Cardiovascular Diseases |x drug therapy |z United States |v Congresses | |
| 650 | 4 | |a Cardiovascular agents |x Testing |v Congresses | |
| 650 | 4 | |a Drug Evaluation |x standards |z United States |v Congresses | |
| 650 | 4 | |a Drug Evaluation |z United States |v Congresses | |
| 650 | 4 | |a Hypertension |x drug therapy |z United States |v Congresses | |
| 650 | 4 | |a Hypotensive agents |x Testing |v Congresses | |
| 650 | 4 | |a Risk |z United States |v Congresses | |
| 650 | 0 | 7 | |a Arzneimittelprüfung |0 (DE-588)4128030-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Antihypertonikum |0 (DE-588)4002286-9 |2 gnd |9 rswk-swf |
| 651 | 4 | |a USA | |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |y 1989 |z Philadelphia Pa. |2 gnd-content | |
| 689 | 0 | 0 | |a Antihypertonikum |0 (DE-588)4002286-9 |D s |
| 689 | 0 | 1 | |a Arzneimittelprüfung |0 (DE-588)4128030-1 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Morganroth, Joel |e Sonstige |4 oth | |
| 830 | 0 | |a Developments in cardiovascular medicine |v 112 |w (DE-604)BV000000660 |9 112 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-002679189 | ||
Record in the Search Index
| _version_ | 1804118498131050496 |
|---|---|
| any_adam_object | |
| building | Verbundindex |
| bvnumber | BV004308504 |
| callnumber-first | R - Medicine |
| callnumber-label | RC667 |
| callnumber-raw | RC667 RM345 |
| callnumber-search | RC667 RM345 |
| callnumber-sort | RC 3667 |
| callnumber-subject | RC - Internal Medicine |
| ctrlnum | (OCoLC)21376754 (DE-599)BVBBV004308504 |
| dewey-full | 615/.71 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615/.71 |
| dewey-search | 615/.71 |
| dewey-sort | 3615 271 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02157nam a2200517 cb4500</leader><controlfield tag="001">BV004308504</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">910404s1990 |||| 10||| engod</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0792307569</subfield><subfield code="9">0-7923-0756-9</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)21376754</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV004308504</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC667</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM345</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.71</subfield><subfield code="2">20</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Use and approval of antihypertensive agents and surrogate endpoints for the approval of drugs affecting antiarrhythmic heart failure and hypolipidemia</subfield><subfield code="b">proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 - November 1, 1989</subfield><subfield code="c">ed. by Joel Morganroth ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Boston u.a.</subfield><subfield code="b">Kluwer</subfield><subfield code="c">1990</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">X, 230 S.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Developments in cardiovascular medicine</subfield><subfield code="v">112</subfield></datafield><datafield tag="610" ind1="2" ind2="4"><subfield code="a">United States.</subfield><subfield code="b">Food and Drug Administration</subfield></datafield><datafield tag="610" ind1="2" ind2="4"><subfield code="a">United States.</subfield><subfield code="b">Food and Drug Administration</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antihypertensive Agents</subfield><subfield code="z">United States</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cardiovascular Diseases</subfield><subfield code="x">drug therapy</subfield><subfield code="z">United States</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cardiovascular agents</subfield><subfield code="x">Testing</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Evaluation</subfield><subfield code="x">standards</subfield><subfield code="z">United States</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Evaluation</subfield><subfield code="z">United States</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hypertension</subfield><subfield code="x">drug therapy</subfield><subfield code="z">United States</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hypotensive agents</subfield><subfield code="x">Testing</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Risk</subfield><subfield code="z">United States</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelprüfung</subfield><subfield code="0">(DE-588)4128030-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Antihypertonikum</subfield><subfield code="0">(DE-588)4002286-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">USA</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="y">1989</subfield><subfield code="z">Philadelphia Pa.</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Antihypertonikum</subfield><subfield code="0">(DE-588)4002286-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Arzneimittelprüfung</subfield><subfield code="0">(DE-588)4128030-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Morganroth, Joel</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Developments in cardiovascular medicine</subfield><subfield code="v">112</subfield><subfield code="w">(DE-604)BV000000660</subfield><subfield code="9">112</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-002679189</subfield></datafield></record></collection> |
| genre | (DE-588)1071861417 Konferenzschrift 1989 Philadelphia Pa. gnd-content |
| genre_facet | Konferenzschrift 1989 Philadelphia Pa. |
| geographic | USA |
| geographic_facet | USA |
| id | DE-604.BV004308504 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-09T16:11:15Z |
| institution | BVB |
| isbn | 0792307569 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-002679189 |
| oclc_num | 21376754 |
| open_access_boolean | |
| owner | DE-12 |
| owner_facet | DE-12 |
| physical | X, 230 S. |
| publishDate | 1990 |
| publishDateSearch | 1990 |
| publishDateSort | 1990 |
| publisher | Kluwer |
| record_format | marc |
| series | Developments in cardiovascular medicine |
| series2 | Developments in cardiovascular medicine |
| spelling | Use and approval of antihypertensive agents and surrogate endpoints for the approval of drugs affecting antiarrhythmic heart failure and hypolipidemia proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 - November 1, 1989 ed. by Joel Morganroth ... Boston u.a. Kluwer 1990 X, 230 S. txt rdacontent n rdamedia nc rdacarrier Developments in cardiovascular medicine 112 United States. Food and Drug Administration United States. Food and Drug Administration Congresses Antihypertensive Agents United States Congresses Cardiovascular Diseases drug therapy United States Congresses Cardiovascular agents Testing Congresses Drug Evaluation standards United States Congresses Drug Evaluation United States Congresses Hypertension drug therapy United States Congresses Hypotensive agents Testing Congresses Risk United States Congresses Arzneimittelprüfung (DE-588)4128030-1 gnd rswk-swf Antihypertonikum (DE-588)4002286-9 gnd rswk-swf USA (DE-588)1071861417 Konferenzschrift 1989 Philadelphia Pa. gnd-content Antihypertonikum (DE-588)4002286-9 s Arzneimittelprüfung (DE-588)4128030-1 s DE-604 Morganroth, Joel Sonstige oth Developments in cardiovascular medicine 112 (DE-604)BV000000660 112 |
| spellingShingle | Use and approval of antihypertensive agents and surrogate endpoints for the approval of drugs affecting antiarrhythmic heart failure and hypolipidemia proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 - November 1, 1989 Developments in cardiovascular medicine United States. Food and Drug Administration United States. Food and Drug Administration Congresses Antihypertensive Agents United States Congresses Cardiovascular Diseases drug therapy United States Congresses Cardiovascular agents Testing Congresses Drug Evaluation standards United States Congresses Drug Evaluation United States Congresses Hypertension drug therapy United States Congresses Hypotensive agents Testing Congresses Risk United States Congresses Arzneimittelprüfung (DE-588)4128030-1 gnd Antihypertonikum (DE-588)4002286-9 gnd |
| subject_GND | (DE-588)4128030-1 (DE-588)4002286-9 (DE-588)1071861417 |
| title | Use and approval of antihypertensive agents and surrogate endpoints for the approval of drugs affecting antiarrhythmic heart failure and hypolipidemia proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 - November 1, 1989 |
| title_auth | Use and approval of antihypertensive agents and surrogate endpoints for the approval of drugs affecting antiarrhythmic heart failure and hypolipidemia proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 - November 1, 1989 |
| title_exact_search | Use and approval of antihypertensive agents and surrogate endpoints for the approval of drugs affecting antiarrhythmic heart failure and hypolipidemia proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 - November 1, 1989 |
| title_full | Use and approval of antihypertensive agents and surrogate endpoints for the approval of drugs affecting antiarrhythmic heart failure and hypolipidemia proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 - November 1, 1989 ed. by Joel Morganroth ... |
| title_fullStr | Use and approval of antihypertensive agents and surrogate endpoints for the approval of drugs affecting antiarrhythmic heart failure and hypolipidemia proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 - November 1, 1989 ed. by Joel Morganroth ... |
| title_full_unstemmed | Use and approval of antihypertensive agents and surrogate endpoints for the approval of drugs affecting antiarrhythmic heart failure and hypolipidemia proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 - November 1, 1989 ed. by Joel Morganroth ... |
| title_short | Use and approval of antihypertensive agents and surrogate endpoints for the approval of drugs affecting antiarrhythmic heart failure and hypolipidemia |
| title_sort | use and approval of antihypertensive agents and surrogate endpoints for the approval of drugs affecting antiarrhythmic heart failure and hypolipidemia proceedings of the tenth annual symposium on new drugs devices october 31 november 1 1989 |
| title_sub | proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 - November 1, 1989 |
| topic | United States. Food and Drug Administration United States. Food and Drug Administration Congresses Antihypertensive Agents United States Congresses Cardiovascular Diseases drug therapy United States Congresses Cardiovascular agents Testing Congresses Drug Evaluation standards United States Congresses Drug Evaluation United States Congresses Hypertension drug therapy United States Congresses Hypotensive agents Testing Congresses Risk United States Congresses Arzneimittelprüfung (DE-588)4128030-1 gnd Antihypertonikum (DE-588)4002286-9 gnd |
| topic_facet | United States. Food and Drug Administration United States. Food and Drug Administration Congresses Antihypertensive Agents United States Congresses Cardiovascular Diseases drug therapy United States Congresses Cardiovascular agents Testing Congresses Drug Evaluation standards United States Congresses Drug Evaluation United States Congresses Hypertension drug therapy United States Congresses Hypotensive agents Testing Congresses Risk United States Congresses Arzneimittelprüfung Antihypertonikum USA Konferenzschrift 1989 Philadelphia Pa. |
| volume_link | (DE-604)BV000000660 |
| work_keys_str_mv | AT morganrothjoel useandapprovalofantihypertensiveagentsandsurrogateendpointsfortheapprovalofdrugsaffectingantiarrhythmicheartfailureandhypolipidemiaproceedingsofthetenthannualsymposiumonnewdrugsdevicesoctober31november11989 |